# Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT00429026** · PHASE2 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 40 (actual)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Melphalan
- **DRUG:** Cyclophosphamide
- **PROCEDURE:** Stem Cell Transplant

## Key facts

- **NCT ID:** NCT00429026
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2008-03
- **Final completion:** 2008-03
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** Slow accrual, study terminated.
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00429026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00429026, "Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00429026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*